Fig. 8. Graphical representation of a series of test compounds ranked by rates of time-dependent inhibition (
kobs). The line includes new chemical entities (drug candidates), and marketed drugs are indicated with filled triangles (▲) (
Zimmerlin et al., 2011). Reprinted from Drug Metab. Dispos., Vol. 39, Zimmerlin, A., Trunzer, M. and Faller, B., CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs, pages 1039-1046 (
Zimmerlin et al., 2011), Copyright (2011), with permission from American Society for Pharmacology and Experimental Therapeutics.
